• No results found

From undifferentiated arthritis to rheumatoid arthritis : epidemiology, immunology and early intervention Gillet-van Dongen, H.

N/A
N/A
Protected

Academic year: 2021

Share "From undifferentiated arthritis to rheumatoid arthritis : epidemiology, immunology and early intervention Gillet-van Dongen, H."

Copied!
9
0
0

Bezig met laden.... (Bekijk nu de volledige tekst)

Hele tekst

(1)

From undifferentiated arthritis to rheumatoid arthritis : epidemiology, immunology and early intervention

Gillet-van Dongen, H.

Citation

Gillet-van Dongen, H. (2010, October 5). From undifferentiated arthritis to rheumatoid arthritis : epidemiology, immunology and early intervention.

Retrieved from https://hdl.handle.net/1887/16012

Version: Corrected Publisher’s Version

License: Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden

Downloaded from: https://hdl.handle.net/1887/16012

Note: To cite this publication please use the final published version (if

applicable).

(2)

From undifferentiated arthritis to rheumatoid arthritis:

epidemiology, immunology and early intervention

Henrike Gillet-van Dongen

(3)

Het onderzoek beschreven in dit proefschrift werd uitgevoerd op de afdeling Reuma- tologie van het Leids Universitair Medisch Centrum te Leiden. Het onderzoek werd financiëel ondersteund door een persoonsgebonden ZonMw AGIKO-stipendium, getiteld “De onderliggende modulatie van de autoantigeen-specifieke afweer bij de behandeling van ongedifferentiëerde artritis”, projectnummer 920-03-259.

© Henrike Gillet-van Dongen, 2010. Hoofdstuk 2: Clinical and Experimental Rheumato- logy, 2004. Hoofdstuk 3 en 7: British Medical Journal Group, resp. 2005 en 2008. Hoofd- stuk 4, 5, 6 en 8: American College of Rheumatology, resp. 2007, 2010, 2007 en 2008.

Hoofdstuk 9: The National Academy of Sciences of the USA, 2004.

ISBN: 978-90-8559-052-1

Omslagontwerp: Manon Kuiper

Lay-out en drukwerk: Optima Grafische Communicatie

De druk van dit proefschrift werd gedeeltelijk financiëel ondersteund door ABBOTT B.V., AstraZeneca, J.E. Jurriaanse Stichting, Het Reumafonds, Merck Sharp & Dohme B.V., Roche, Schering-Plough, Sectra DXR-online, TEVA Pharma en UCB Pharma.

(4)

From undifferentiated arthritis to rheumatoid arthritis:

epidemiology, immunology and early intervention

PROEFSCHRIFT

ter verkrijging van

de graad Doctor aan de Universiteit Leiden,

op gezag van de Rector Magnificus prof. mr. P.F. van der Heijden,

volgens besluit van het College van Promoties te verdedigen op dinsdag 5 oktober 2010

klokke 15.00 uur

door

Henrike Gillet-van Dongen

geboren te Dordrecht in 1975

(5)

Promotiecommissie

Promotores: Prof. dr. T.W.J. Huizinga Prof. dr. R.E.M. Toes

Overige leden: Prof. dr. M. Boers (Vrije Universiteit, Amsterdam) Prof. dr. D.M.F.M. van der Heijde

Prof. dr. R.R.P. de Vries Prof. dr. F. Koning Dr. C.F. Allaart

(6)

‘On ne voit bien qu’avec le coeur. L’essentiel est invisible pour les yeux.’

Antoine de Saint-Exupéry (1900 - 1944)

(7)
(8)

Contents

Chapter 1 Introduction 9

Part I Undifferentiated arthritis

Chapter 2 Undifferentiated arthritis - Disease

course assessed in several inception cohorts

23

Chapter 3 Comparison of long term outcome of patients with

rheumatoid arthritis presenting with undifferentiated arthritis or with rheumatoid arthritis: an observational cohort study

35

Chapter 4 Efficacy of methotrexate treatment in patients with probable rheumatoid arthritis. A double-blind, randomized,

placebo-controlled trial

49

Chapter 5 Validity of the disease activity score in undifferentiated arthritis

67

Chapter 6 A prediction rule for disease outcome in patients with recent-onset undifferentiated arthritis.

How to guide individual treatment decisions

83

Chapter 7 Pretreatment serum levels of anti-cyclic citrullinated peptide antibodies are associated with the response to methotrexate in recent-onset arthritis

99

Part II Rheumatoid arthritis

Chapter 8 Suppressor activity among CD4+, CD25++ T cells is

discriminated by membrane-bound tumor necrosis factor alpha

105

Chapter 9 Functional regulatory immune responses against human cartilage glycoprotein-39 in health vs. proinflammatory responses in rheumatoid arthritis

125

Chapter 10 Summary and discussion 143

Chapter 11 Nederlandse samenvatting 157

Curriculum Vitae Publications

166 167

(9)

Referenties

GERELATEERDE DOCUMENTEN

at baseline, and at 12 months (not shown). It can be seen that the number of tender joints involved is larger than the number of swollen joints. In figure 1 B, the scores of

A prediction rule was developed using data from the Leiden Early Arthritis Clinic, an inception cohort of patients with recent-onset arthritis (n = 1,700).. The

(A) Pretreatment anti-cyclic citrullinated peptide antibodies (ACPA) levels in methotrexate (MTX) responders versus non-responders within ACPA-positive patients with

Since FoxP3 is the most commonly used marker for human CD4+,CD25+ Treg cells thus far (19), and because surface CD127 expression is inversely associated with the presence

HC gp-39-Specific Immune Reactivity Is Characterized by IL-10 Production Because various observations indicate the presence of HC gp-39-directed T cells in the human T cell

Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled

Indien werd vereist dat patiënten bij een eerste beoordeling door een reumatoloog een artritis hadden en dat voor de diagnose reumatoïde artritis moest worden voldaan aan de

Zij heeft een weten- schapsstage gelopen bij de afdeling Reumatologie (begeleiding: prof. Kaijzel) getiteld ‘Associative and functional aspects of four in- terleukin-1